media – Page 177 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Alzheimer’s Blood Test Could Soon Replace Invasive Spinal Taps and Brain Scans

Historically, Alzheimer’s disease was primarily diagnosed based on observable symptoms, particularly when individuals started exhibiting memory and cognitive difficulties. However, it’s been revealed through research that up to a third of individuals diagnosed with Alzheimer’s based solely on cognitive symptoms have been incorrectly diagnosed, with their symptoms stemming from other causes. The accurate identification of Alzheimer’s disease has become increasingly crucial, especially since the introduction of the first treatments that can slow the disease’s progression, along with other promising drugs currently in development. These treatments are potentially more effective when administered early, highlighting the need for early detection of the disease. Therefore, to qualify for Alzheimer’s therapies, patients must show cognitive impairment and test positive for amyloid plaques, which are distinctive to Alzheimer’s. Techniques like amyloid positron emission tomography (PET) brain scans, cerebrospinal fluid analyses, and blood tests are used to detect brain amyloid plaques. However, these are only employed ...
- Source: drugdu
- 169
- February 28, 2024
Teva, Jiangsu Nhwa Ink Strategic Partnership Deal Focused on Patient Access to Austedo in China

Don Tracy, Associate Editor Collaboration aims to leverage Nhwa’s expertise in the country’s neuro-psychiatric health sector. Today, Teva announced that it has entered into a collaboration with Nhwa Pharmaceutical Co., Ltd with the goal of providing easier access to Teva’s drug Austedo in China. Austedo focuses on the treatment of neurodegenerative and movement disorders, particularly chorea associated with Huntington disease (HD) and tardive dyskinesia (TD) in adults. According to Teva, the partnership is a part of its goal of expanding the medication as a global brand, as it earned approximately over $1.2 billion in profits last year. Further, Teva reported that Austedo is the first deuterated drug to be approved in China. Deuteration involves replacing hydrogen atoms with deuterium, which can slow down the drug’s metabolism, allowing for less frequent dosing and potentially improving patient compliance.1 “We are committed to addressing the pressing needs of patients in China with more ...
- Source: drugdu
- 127
- February 28, 2024
Asthma Medication Xolair May Reduce Peanut Allergies, New Study Finds

Mike Hollan FDA has approved the medication in adults and children with allergies. A peanut allergy can be a difficult and terrifying thing to live with. People with these allergies have to be on constant alert, as coming into contact with even a small amount of the food can cause a severe reaction. Thousands of Americans live with these allergies, and they are responsible for a similar number of emergency room visits. Typically, the best way to treat a peanut is to just avoid them altogether, which can be difficult due to how common nuts and nut oils are used in cooking. A recent announcement from Novartis, however, may make life a lot easier (and much less scary) for people living with these allergies. Novartis released that data from a new study which suggests that asthma medication Xolair can be used to treat certain food allergies, including nuts, eggs, milk, ...
- Source: drugdu
- 95
- February 28, 2024
Qyuns Therapeutics passed the IPO hearing on the Main Board of the Hong Kong Stock Exchange

According to the Hong Kong Stock Exchange, on February 26, Jiangsu Qyuns Therapeutics-B passed the IPO hearing on the main board of the Hong Kong Stock Exchange and will be listed soon. It is reported that Qyuns Therapeutics was established in 2015. It is a clinical-stage biotechnology company completely focused on biotherapeutics of autoimmune and allergic diseases, covering four major disease areas: skin, rheumatism, respiratory and digestive tract diseases. According to its official website, based on its complete independent innovation capabilities, Qyuns Therapeutics has formed two core products, QX002N and QX005N, as well as a product pipeline of seven other drug candidates. One variety has been accepted by BLA, one is in clinical phase 3, and four varieties are in clinical phase 2 and 1 respectively. The indications cover silver eyebrow disease, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, It covers four major disease areas including asthma, inflammatory bowel disease, ...
- Source: drugdu
- 100
- February 28, 2024
Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season

The World Health Organization (WHO) today announced the recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The announcement was made at an information session after a 4-day meeting on the Composition of Influenza Virus Vaccines. The meeting is held twice annually, once for the southern and once for the northern hemisphere. WHO organizes these consultations with an advisory group of experts gathered from WHO Collaborating Centres and WHO Essential Regulatory Laboratories to analyse influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS). The recommendations issued are used by the national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season. The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses, including ...
- Source: drugdu
- 88
- February 28, 2024
PhaSER Biomedical receives $2.3m drug discovery grant from the Gates Foundation

Every year, tuberculosis, malaria and HIV cause over five million deaths worldwide PhaSER Biomedical has received a grant from the Bill & Melinda Gates Foundation worth $2.3m to accelerate drug discovery and development. PhaSER’s technology, 8HUM, will become a collaborating institution within the Global Health Discovery Collaboratory Programme, funded by the Gates Foundation. As part of the three-year programme, PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in the metabolism and disposition of drugs, to all grantees of the foundation. Collaborating researchers involved in combating diseases including malaria, tuberculosis (TB), HIV, pandemic preparedness and non-hormonal contraception will be provided with access to the drug discovery and development platform. Considered the ‘big three’ infectious diseases, TB, malaria and HIV are responsible for more than five million deaths worldwide every year. Formed in 2022 in collaboration with researchers at the University of Dundee, CXR Biosciences, Taconic Farms and ...
- Source: drugdu
- 139
- February 28, 2024
Researchers develop terahertz biosensor to detect skin cancer for early diagnosis

Results from the study could also be used for other forms of cancer and diseases Researchers from the University of Glasgow and Queen Mary University of London have developed a new biosensor using terahertz (THz) waves that can detect skin cancer with strong sensitivity. Published in the IEEE Transactions on Biomedical Engineering, the study results could pave the way for easier and earlier diagnoses of skin cancer and potentially other cancers and diseases. Affecting one in four men and one in five women at least once in their lifetime in the UK, skin cancer is an abnormal growth of skin cells that involves three major types: basal cell carcinoma (BCC), squamous cell carcinoma and melanoma. Most skin cancer is often detected using traditional methods that involve expensive, time-consuming CT and PET scans, and invasive higher-frequency technology. After exploring the potential of THz metasurfaces, researchers designed the biosensor to detect subtle ...
- Source: drugdu
- 157
- February 28, 2024
BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062

WUXI, China, Feb. 25, 2024 /PRNewswire/ — BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 clinical study of the novel, oral endothelin A (ETA)-receptor selective antagonist SC0062, currently under development for chronic kidney disease (CKD), including IgAN and diabetic kidney disease (DKD). The enrollment of DKD cohort is ongoing with expected completion by the end of Q2 2024. “We appreciate the dedication of our colleagues and collaborators. The IgAN cohort enrollment was initiated in June 2023, and we enrolled all 120 subjects in less than 9 months. Thanks to the investigators, their teams, patients, and related BioCity colleagues”, Dr. Ivy Wang, co-founder and executive vice president of BioCity, stated. This accomplishment highlights BioCity’s ability to coordinate resources and operate efficiently in clinical trials, and further solidifies its leading position in the ...
- Source: drugdu
- 145
- February 28, 2024
TransThera initiates IND-Enabling studies for TT-02332, a novel, highly potent and CNS-penetrating NLRP3 inhibitor

NANJING, China and GAITHURSBURG, Md., Feb. 26, 2024 /PRNewswire/ — TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor. The NLRP3 inflammasome is a pivotal component of the human innate immune system. Aberrant activation of NLRP3 is strongly linked with a variety of inflammatory disorders, including obesity, neurodegenerative diseases, NASH, inflammatory bowel disease (IBD), dermatitis, and atherosclerosis. “Immuno-inflammation is one of TransThera’s key therapeutic areas of interest. Over the past three years, we have achieved breakthroughs with the NLRP3 inhibitor program.” said Jennifer Sheng, Vice President of Biology at TransThera. “Our clinical candidate compound TT-02332 is a highly potent NLRP3 inhibitor that has shown promising efficacy in a number of disease-relevant in vivo animal models. The compound exhibits desirable pharmacokinetic/ pharmacodynamic (PK/PD) properties, suitable for once-daily dosing. TT-02332 demonstrates an ...
- Source: drugdu
- 143
- February 28, 2024
Zdravookhraneniye 2024 Moscow Russia

Organiser: Russia ZAO Exhibition Co., LTD Time: 02 – 06 December 2024 Exhibition hall: Expocentre Exhibition Center Product categories: Diagnostic equipment: X-ray diagnostic equipment, ultrasonic diagnostic equipment, functional examination equipment, endoscopy equipment, nuclear medicine equipment, experimental diagnostic equipment, pathological diagnostic equipment, diagnostic imaging equipment, chromatographic analyzer, consulting room analyzer, dialysis and transplant surgery Treatment equipment: clinical radiology equipment; Clinical testing equipment and reagents, ward nursing equipment, surgery equipment, radiotherapy equipment, nuclear medicine treatment equipment, physical and chemical equipment, laser equipment, dialysis treatment equipment, temperature freezing equipment, first aid equipment Auxiliary equipment: disinfection and sterilization equipment, refrigeration equipment, central suction and oxygen supply system, air conditioning equipment, pharmaceutical machinery and equipment, blood bank equipment, medical data processing equipment, medical video and photography equipment, medical air pump system cosmetic equipment; Ophthalmic equipment and treatment technology and materials, dental equipment and instruments, dental repair systems and instruments, oral plastic surgery materials and tools, dental ...
- Source: drugdu
- 181
- February 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.